Renovaro (RENB) Competitors $0.27 -0.03 (-9.15%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.26 -0.01 (-1.85%) As of 07/11/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. DSGN, LIMN, SXTC, KOD, TVRD, ACIU, EPRX, ENGN, ELDN, and YMABShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Design Therapeutics (DSGN), Liminatus Pharma (LIMN), China SXT Pharmaceuticals (SXTC), Kodiak Sciences (KOD), Tvardi Therapeutics (TVRD), AC Immune (ACIU), Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Eledon Pharmaceuticals (ELDN), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Its Competitors Design Therapeutics Liminatus Pharma China SXT Pharmaceuticals Kodiak Sciences Tvardi Therapeutics AC Immune Eupraxia Pharmaceuticals enGene Eledon Pharmaceuticals Y-mAbs Therapeutics Renovaro (NASDAQ:RENB) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Do analysts prefer RENB or DSGN? Design Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 2.04%. Given Design Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Design Therapeutics is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is RENB or DSGN more profitable? Design Therapeutics' return on equity of -22.85% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -60.38% -47.04% Design Therapeutics N/A -22.85%-22.02% Does the media favor RENB or DSGN? In the previous week, Renovaro had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Renovaro and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.93 beat Renovaro's score of 0.22 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Renovaro 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, RENB or DSGN? Design Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$88.43M-$0.77-0.35Design TherapeuticsN/AN/A-$49.59M-$0.99-3.96 Do insiders and institutionals hold more shares of RENB or DSGN? 71.4% of Renovaro shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 21.7% of Renovaro shares are owned by insiders. Comparatively, 31.2% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, RENB or DSGN? Renovaro has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. SummaryDesign Therapeutics beats Renovaro on 8 of the 12 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.47M$2.94B$5.56B$9.10BDividend YieldN/A2.41%5.06%4.02%P/E Ratio-0.3520.8528.2620.26Price / SalesN/A263.32427.70153.06Price / CashN/A42.1137.1257.67Price / Book0.307.638.045.49Net Income-$88.43M-$55.05M$3.19B$250.45M7 Day Performance-2.88%8.43%3.62%4.79%1 Month Performance-26.09%8.14%5.98%9.59%1 Year Performance-81.38%1.62%29.39%16.41% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro1.935 of 5 stars$0.27-9.2%N/A-81.4%$46.47MN/A-0.3520News CoverageDSGNDesign Therapeutics0.6318 of 5 stars$3.61-4.4%$4.00+11.0%-10.1%$202.67MN/A-3.6140News CoverageLIMNLiminatus PharmaN/A$7.77+12.1%N/AN/A$202.14MN/A0.00N/APositive NewsAnalyst UpgradeGap DownSXTCChina SXT Pharmaceuticals0.9363 of 5 stars$1.72-8.5%N/A-82.9%$201.89M$1.93M0.0090Gap DownKODKodiak Sciences4.0879 of 5 stars$3.83+3.1%$9.00+135.3%+51.0%$201.75MN/A-1.0590News CoverageTVRDTvardi TherapeuticsN/A$21.52-4.2%$71.50+232.2%N/A$201.43M$7.14M0.0080News CoverageAnalyst ForecastAnalyst RevisionGap UpACIUAC Immune2.2547 of 5 stars$2.01+0.8%$12.00+498.5%-44.0%$200.82M$31.02M-3.45140Analyst RevisionEPRXEupraxia Pharmaceuticals2.4101 of 5 stars$5.52+2.1%$11.00+99.5%+93.6%$198.32MN/A-7.2629Positive NewsGap UpENGNenGene2.6531 of 5 stars$3.90+2.6%$23.29+497.2%-63.5%$196.94MN/A-2.3431Trending NewsELDNEledon Pharmaceuticals1.5156 of 5 stars$3.30+6.2%$9.00+172.4%+34.6%$196.65MN/A-1.5610Analyst RevisionYMABY-mAbs Therapeutics4.1963 of 5 stars$4.25-1.2%$15.60+267.1%-65.0%$195.38M$87.68M-6.74150Positive News Related Companies and Tools Related Companies Design Therapeutics Alternatives Liminatus Pharma Alternatives China SXT Pharmaceuticals Alternatives Kodiak Sciences Alternatives Tvardi Therapeutics Alternatives AC Immune Alternatives Eupraxia Pharmaceuticals Alternatives enGene Alternatives Eledon Pharmaceuticals Alternatives Y-mAbs Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
